1/2상모집 중

Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

연구 개요

The goals of this clinical study are to first learn more about safety and dosing of the study drug GS-4321 in healthy participants. The study will then learn about the safety and effectiveness of GS-4321 in participants with chronic hepatitis delta (CHD). The primary objective of Phase 1 of this study is to evaluate the safety, tolerability and Pharmacokinetics (PK) of the escalating single doses of GS-4321 administered in healthy participants. The primary objective of Phase 2 of this study is to evaluate the efficacy and safety of the multiple escalating doses of GS-4321 in participants with CHD.

스폰서
리드: 길리어드
적응증
Chronic Hepatitis Delta
중재
GS-4321, GS-4321 Placebo, GS-4321
목표 등록
200
시작일
2025-07-31
완료(예정)
2030-01-01

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.